OPKO Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by OPKO Health, Inc. on February 19, 2021. The filing discloses actions taken by the Compensation Committee of the Board of Directors regarding executive compensation adjustments and equity grants.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on specific compensatory arrangements.
Material Changes and Compensation Actions
On February 19, 2021, the Compensation Committee approved the following changes:
- Stock Options: Granted to named executive officers with an exercise price of $4.81 per share (fair market value on grant date). Options vest ratably over four years and expire on the tenth anniversary of the grant date.
- Option Allocation:
- Phillip Frost (CEO/Chairman): 400,000 shares
- Jane H. Hsiao (Vice Chairman/CTO): 400,000 shares
- Steven D. Rubin (EVP): 350,000 shares
- Adam Logal (SVP/CFO): 350,000 shares
- Cash Bonus: Approved a one-time cash bonus of $500,000 for Adam Logal.
- Salary Increase: Approved an annual salary increase for Adam Logal from $600,000 to $700,000.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, outlook, management commentary on business performance, or specific risk factors beyond the standard disclosure of executive compensation changes.
Key Facts for Investor Verification
- Verify the total number of shares authorized for issuance under the company's equity incentive plans to ensure these grants are covered.
- Confirm the impact of the $500,000 cash bonus and $100,000 annual salary increase on the company's near-term operating expenses.
- Review the vesting schedule details to understand the future dilution impact over the four-year period.
- Check the current trading price of OPKO stock relative to the $4.81 exercise price to assess the intrinsic value of the granted options.